A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells

Takatsugu Okegawa, Jennifer R. Sayne, Kikuo Nutahara, Rey Chen Pong, Hossain Saboorian, Wareef Kabbani, Eiji Higashihara, Jer Tsong Hsieh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Coxsackie and adenovirus receptor is a high affinity receptor for adenovirus type 5. To our knowledge the expression profile of coxsackie and adenovirus receptor in renal cancer has not been described. We evaluated the expression of coxsackie and adenovirus receptor in human renal cancer specimens and determined whether the histone deacetylase inhibitor FK-228 (Astelas Pharmaceutical, Osaka, Japan) increases the efficiency of adenoviral infections in renal carcinoma cells in vivo and in vitro. Materials and Methods: We used randomly selected renal cancer specimens. Specimens were analyzed for coxsackie and adenovirus receptor expression using reverse transcriptase-polymerase chain reaction and immunohistochemistry. In vitro experiments on cytotoxicity were performed to determine a nontoxic dose of FK-228 for renal cancer cells. The level of coxsackie and adenovirus receptor expression was determined by fluorescence activated cell scanning and/or reverse transcriptase-polymerase chain reaction in FK-228 treated renal cancer cells. The effect in vivo on adenoviral gene expression was investigated in athymic mice. Results: In several human renal cancer specimens a loss of or decreased coxsackie and adenovirus receptor expression was detected by reverse transcriptase-polymerase chain reaction based analysis and immunohistochemistry. The nontoxic dose of FK-228 for renal carcinoma cells was 0.5 ng/ml. Treatment of cancer cells with 0.5 ng/ml FK-228 increased levels of coxsackie and adenovirus receptor RNA and acetylated histone H3. This increase was associated with an approximately 10-fold increase in adenoviral infection, as evidenced by increased transgene expression from a β-galactosidase containing adenoviral vector. Intravenous administration of FK-228 enhanced coxsackie and adenovirus receptor expression in athymic mice. The combination of β-galactosidase adenovirus and FK-228 was significantly more effective than adenovirus only in A498 cells 3 weeks after treatment in vivo. The combination of p21 adenovirus and FK-228 resulted in significant tumor inhibition in vitro and in vivo. Conclusions: In human renal cancer specimens a loss of or decrease in coxsackie and adenovirus receptor expression may be an early event in renal cancer progression. Pretreatment with FK-228 may increase tumor cell sensitivity to adenoviral gene therapy vectors.

Original languageEnglish (US)
Pages (from-to)1148-1156
Number of pages9
JournalJournal of Urology
Volume177
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Coxsackie and Adenovirus Receptor-Like Membrane Protein
Histone Deacetylase Inhibitors
Renal Cell Carcinoma
Kidney Neoplasms
Infection
Reverse Transcriptase Polymerase Chain Reaction
Adenoviridae
Galactosidases
Nude Mice
Immunohistochemistry
Neoplasms
Transgenes
Intravenous Administration
Genetic Therapy
Histones
Japan
Fluorescence

Keywords

  • CXADR protein
  • disease progression
  • histone deacetylases
  • human
  • kidney
  • kidney neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Okegawa, T., Sayne, J. R., Nutahara, K., Pong, R. C., Saboorian, H., Kabbani, W., ... Hsieh, J. T. (2007). A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells. Journal of Urology, 177(3), 1148-1156. https://doi.org/10.1016/j.juro.2006.10.034

A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells. / Okegawa, Takatsugu; Sayne, Jennifer R.; Nutahara, Kikuo; Pong, Rey Chen; Saboorian, Hossain; Kabbani, Wareef; Higashihara, Eiji; Hsieh, Jer Tsong.

In: Journal of Urology, Vol. 177, No. 3, 03.2007, p. 1148-1156.

Research output: Contribution to journalArticle

Okegawa, T, Sayne, JR, Nutahara, K, Pong, RC, Saboorian, H, Kabbani, W, Higashihara, E & Hsieh, JT 2007, 'A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells', Journal of Urology, vol. 177, no. 3, pp. 1148-1156. https://doi.org/10.1016/j.juro.2006.10.034
Okegawa T, Sayne JR, Nutahara K, Pong RC, Saboorian H, Kabbani W et al. A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells. Journal of Urology. 2007 Mar;177(3):1148-1156. https://doi.org/10.1016/j.juro.2006.10.034
Okegawa, Takatsugu ; Sayne, Jennifer R. ; Nutahara, Kikuo ; Pong, Rey Chen ; Saboorian, Hossain ; Kabbani, Wareef ; Higashihara, Eiji ; Hsieh, Jer Tsong. / A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells. In: Journal of Urology. 2007 ; Vol. 177, No. 3. pp. 1148-1156.
@article{ddddb375a9cf47db8ce243e314f0d969,
title = "A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells",
abstract = "Purpose: Coxsackie and adenovirus receptor is a high affinity receptor for adenovirus type 5. To our knowledge the expression profile of coxsackie and adenovirus receptor in renal cancer has not been described. We evaluated the expression of coxsackie and adenovirus receptor in human renal cancer specimens and determined whether the histone deacetylase inhibitor FK-228 (Astelas Pharmaceutical, Osaka, Japan) increases the efficiency of adenoviral infections in renal carcinoma cells in vivo and in vitro. Materials and Methods: We used randomly selected renal cancer specimens. Specimens were analyzed for coxsackie and adenovirus receptor expression using reverse transcriptase-polymerase chain reaction and immunohistochemistry. In vitro experiments on cytotoxicity were performed to determine a nontoxic dose of FK-228 for renal cancer cells. The level of coxsackie and adenovirus receptor expression was determined by fluorescence activated cell scanning and/or reverse transcriptase-polymerase chain reaction in FK-228 treated renal cancer cells. The effect in vivo on adenoviral gene expression was investigated in athymic mice. Results: In several human renal cancer specimens a loss of or decreased coxsackie and adenovirus receptor expression was detected by reverse transcriptase-polymerase chain reaction based analysis and immunohistochemistry. The nontoxic dose of FK-228 for renal carcinoma cells was 0.5 ng/ml. Treatment of cancer cells with 0.5 ng/ml FK-228 increased levels of coxsackie and adenovirus receptor RNA and acetylated histone H3. This increase was associated with an approximately 10-fold increase in adenoviral infection, as evidenced by increased transgene expression from a β-galactosidase containing adenoviral vector. Intravenous administration of FK-228 enhanced coxsackie and adenovirus receptor expression in athymic mice. The combination of β-galactosidase adenovirus and FK-228 was significantly more effective than adenovirus only in A498 cells 3 weeks after treatment in vivo. The combination of p21 adenovirus and FK-228 resulted in significant tumor inhibition in vitro and in vivo. Conclusions: In human renal cancer specimens a loss of or decrease in coxsackie and adenovirus receptor expression may be an early event in renal cancer progression. Pretreatment with FK-228 may increase tumor cell sensitivity to adenoviral gene therapy vectors.",
keywords = "CXADR protein, disease progression, histone deacetylases, human, kidney, kidney neoplasms",
author = "Takatsugu Okegawa and Sayne, {Jennifer R.} and Kikuo Nutahara and Pong, {Rey Chen} and Hossain Saboorian and Wareef Kabbani and Eiji Higashihara and Hsieh, {Jer Tsong}",
year = "2007",
month = "3",
doi = "10.1016/j.juro.2006.10.034",
language = "English (US)",
volume = "177",
pages = "1148--1156",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells

AU - Okegawa, Takatsugu

AU - Sayne, Jennifer R.

AU - Nutahara, Kikuo

AU - Pong, Rey Chen

AU - Saboorian, Hossain

AU - Kabbani, Wareef

AU - Higashihara, Eiji

AU - Hsieh, Jer Tsong

PY - 2007/3

Y1 - 2007/3

N2 - Purpose: Coxsackie and adenovirus receptor is a high affinity receptor for adenovirus type 5. To our knowledge the expression profile of coxsackie and adenovirus receptor in renal cancer has not been described. We evaluated the expression of coxsackie and adenovirus receptor in human renal cancer specimens and determined whether the histone deacetylase inhibitor FK-228 (Astelas Pharmaceutical, Osaka, Japan) increases the efficiency of adenoviral infections in renal carcinoma cells in vivo and in vitro. Materials and Methods: We used randomly selected renal cancer specimens. Specimens were analyzed for coxsackie and adenovirus receptor expression using reverse transcriptase-polymerase chain reaction and immunohistochemistry. In vitro experiments on cytotoxicity were performed to determine a nontoxic dose of FK-228 for renal cancer cells. The level of coxsackie and adenovirus receptor expression was determined by fluorescence activated cell scanning and/or reverse transcriptase-polymerase chain reaction in FK-228 treated renal cancer cells. The effect in vivo on adenoviral gene expression was investigated in athymic mice. Results: In several human renal cancer specimens a loss of or decreased coxsackie and adenovirus receptor expression was detected by reverse transcriptase-polymerase chain reaction based analysis and immunohistochemistry. The nontoxic dose of FK-228 for renal carcinoma cells was 0.5 ng/ml. Treatment of cancer cells with 0.5 ng/ml FK-228 increased levels of coxsackie and adenovirus receptor RNA and acetylated histone H3. This increase was associated with an approximately 10-fold increase in adenoviral infection, as evidenced by increased transgene expression from a β-galactosidase containing adenoviral vector. Intravenous administration of FK-228 enhanced coxsackie and adenovirus receptor expression in athymic mice. The combination of β-galactosidase adenovirus and FK-228 was significantly more effective than adenovirus only in A498 cells 3 weeks after treatment in vivo. The combination of p21 adenovirus and FK-228 resulted in significant tumor inhibition in vitro and in vivo. Conclusions: In human renal cancer specimens a loss of or decrease in coxsackie and adenovirus receptor expression may be an early event in renal cancer progression. Pretreatment with FK-228 may increase tumor cell sensitivity to adenoviral gene therapy vectors.

AB - Purpose: Coxsackie and adenovirus receptor is a high affinity receptor for adenovirus type 5. To our knowledge the expression profile of coxsackie and adenovirus receptor in renal cancer has not been described. We evaluated the expression of coxsackie and adenovirus receptor in human renal cancer specimens and determined whether the histone deacetylase inhibitor FK-228 (Astelas Pharmaceutical, Osaka, Japan) increases the efficiency of adenoviral infections in renal carcinoma cells in vivo and in vitro. Materials and Methods: We used randomly selected renal cancer specimens. Specimens were analyzed for coxsackie and adenovirus receptor expression using reverse transcriptase-polymerase chain reaction and immunohistochemistry. In vitro experiments on cytotoxicity were performed to determine a nontoxic dose of FK-228 for renal cancer cells. The level of coxsackie and adenovirus receptor expression was determined by fluorescence activated cell scanning and/or reverse transcriptase-polymerase chain reaction in FK-228 treated renal cancer cells. The effect in vivo on adenoviral gene expression was investigated in athymic mice. Results: In several human renal cancer specimens a loss of or decreased coxsackie and adenovirus receptor expression was detected by reverse transcriptase-polymerase chain reaction based analysis and immunohistochemistry. The nontoxic dose of FK-228 for renal carcinoma cells was 0.5 ng/ml. Treatment of cancer cells with 0.5 ng/ml FK-228 increased levels of coxsackie and adenovirus receptor RNA and acetylated histone H3. This increase was associated with an approximately 10-fold increase in adenoviral infection, as evidenced by increased transgene expression from a β-galactosidase containing adenoviral vector. Intravenous administration of FK-228 enhanced coxsackie and adenovirus receptor expression in athymic mice. The combination of β-galactosidase adenovirus and FK-228 was significantly more effective than adenovirus only in A498 cells 3 weeks after treatment in vivo. The combination of p21 adenovirus and FK-228 resulted in significant tumor inhibition in vitro and in vivo. Conclusions: In human renal cancer specimens a loss of or decrease in coxsackie and adenovirus receptor expression may be an early event in renal cancer progression. Pretreatment with FK-228 may increase tumor cell sensitivity to adenoviral gene therapy vectors.

KW - CXADR protein

KW - disease progression

KW - histone deacetylases

KW - human

KW - kidney

KW - kidney neoplasms

UR - http://www.scopus.com/inward/record.url?scp=33846849623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846849623&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.10.034

DO - 10.1016/j.juro.2006.10.034

M3 - Article

C2 - 17296436

AN - SCOPUS:33846849623

VL - 177

SP - 1148

EP - 1156

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -